Biocon partners with Libbs to launch generic formulations in Brazil
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
The antibody was designed and developed at Abzena’s Cambridge, UK,
The event will be attended by 35,000+ industry professionals
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Subscribe To Our Newsletter & Stay Updated